Xiao Fang Pharma entrusts BOJI CRO to develop traditional Chinese medicine Class 1 new drug "Compound Arborvitae Tincture" (indication for hair loss)
I'm PortAI, I can summarize articles.
Xiao Fang Pharma and BOJI CRO signed a technical entrustment contract, in which BOJI CRO will assist in completing the clinical research and registration of the traditional Chinese medicine Class 1 new drug "Compound Arborvitae Tincture." This cooperation marks an important progress for Xiao Fang Pharma in the field of innovative drugs, as both parties will leverage their respective advantages to enhance R&D efficiency and lay the foundation for product launch
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments